Microsclerotherapy treatment sales will grow through 2036, led by sclerosant type at 36.9% of the product segment in 2026, driven by expanding clinical protocols and institutional procurement requirements. The market was valued at USD 8 billion in 2025 and is expected to be worth USD 11.56 billion by 2036.